UroGen Pharma Ltd.
Biotech stocks rose as several companies reported updates. Attovia Therapeutics (ATTO) jumped over 28% after its Nasdaq debut at $17 and a close at $21.90. American Well (AMWL) gained about 25% after Q2 loss narrowed to $9.6M, though revenue fell to $52.0M. Perrigo (PRGO) swung to Q2 net income of $74.5M. UroGen (URGN) rose after Q2 revenue increased to $72.5M.
UroGen Pharma Ltd. (URGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_995856.htm EXHIBIT 99.1 ex_995856.htm Exhibit 99.1 UroGen Reports $50.4 Million of ZUSDURI ® Revenue and Provides Second Quarter 2026 Financial Results and Highlights ● ZUSDURI ® generated $50.4 million in revenue in the second quarter of 2026, representing 73% quart
UroGen Pharma (Nasdaq: URGN) said the USPTO issued a Notice of Allowance for patent application 18/784,354 covering non-surgical treatment of recurrent low-grade intermediate-risk NMIBC using a thermally gelling mitomycin composition, supported by ENVISION and ATLAS trial data. If issued, the U.S. patent would expire in July 2044 for ZUSDURI and UGN-103.
Over the past 7 days, alphai's AI scored 2 news stories mentioning URGN (UroGen Pharma Ltd.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent URGN coverage spans financial news, market movers and earnings.
In the last 30 days, URGN insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($400K). The most active reporter was Schoenberg Mark, Chief Medical Officer, with 1 filing. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
Commercial launch traction in ZUSDURI is the main narrative, supported by large revenue growth and improved operating performance.
The filing combines a fresh quarterly revenue datapoint with forward-looking regulatory and IP catalysts (patent allowance, NDA submission timing, Phase 1 start for UGN-501).
Patent allowance extends and strengthens IP protection for ZUSDURI and supports the commercial and regulatory defensibility of UGN-103 if approved.
The insider sale is framed as pre-planned (10b5-1) and not a signal, but the article pairs it with concrete operating and regulatory catalysts that can move the stock.
IND clearance is a concrete regulatory milestone that de-risks early clinical progression and can re-rate near-term probability of success.
alphai scores every news story that mentions URGN with an AI model for sentiment and relevance, and aggregates insider trades from UroGen Pharma Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Biotech stocks rose as several companies reported updates. Attovia Therapeutics (ATTO) jumped over 28% after its Nasdaq debut at $17 and a close at $21.90. American Well (AMWL) gained about 25% after Q2 loss narrowed to $9.6M, though revenue fell to $52.0M. Perrigo (PRGO) swung to Q2 net income of $74.5M. UroGen (URGN) rose after Q2 revenue increased to $72.5M.
3 min readUroGen Pharma Ltd. (URGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_995856.htm EXHIBIT 99.1 ex_995856.htm Exhibit 99.1 UroGen Reports $50.4 Million of ZUSDURI ® Revenue and Provides Second Quarter 2026 Financial Results and Highlights ● ZUSDURI ® generated $50.4 million in revenue in the second quarter of 2026, representing 73% quart
6 min readUroGen Pharma (Nasdaq: URGN) said the USPTO issued a Notice of Allowance for patent application 18/784,354 covering non-surgical treatment of recurrent low-grade intermediate-risk NMIBC using a thermally gelling mitomycin composition, supported by ENVISION and ATLAS trial data. If issued, the U.S. patent would expire in July 2044 for ZUSDURI and UGN-103.
4 min readUroGen Pharma said its Chief Medical Officer sold about $400,000 of stock as the final trade under a 10b5-1 plan, while still holding nearly 120,000 shares. The company reported Q1 revenue up 152% to $51 million after Zusduri launch, with $29.2 million from the therapy. UroGen also said the FDA cleared UGN-501 for a planned Phase 1 study starting in Q4.
5 min readUroGen Pharma Ltd. (Nasdaq: URGN) said the FDA cleared its IND for UGN-501, an investigational oncolytic virus for non-muscle invasive bladder cancer. The clearance allows initiation of a planned Phase 1 trial of intravesical UGN-501, with patient enrollment expected to start in Q4 2026 to assess safety, tolerability, and feasibility.
2 min readUroGen Pharma Ltd. (URGN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-3.1 2 ex_979762.htm EXHIBIT 3.1 ex_979762.htm Exhibit 3.1 ARTICLES OF ASSOCIATION OF UROGEN PHARMA LTD. A COMPANY LIMITED BY SHARES UNDER THE COMPANIES LAW, 5759-1999 1. INTERPRETATION 1.1. In these Articles, unless the context requires otherwise, the following capitalized ter
2 min readUroGen Pharma CMO Mark Schoenberg sold 5,222 ordinary shares for about $143,000, according to an SEC Form 4. The filing says he exercised 10,000 options and then sold part of the resulting shares for liquidity. Post-sale, he held 139,763 shares and reported no exercisable options. Shares sold at a weighted average ~$27.30.
5 min readSchoenberg Mark (Chief Medical Officer) sold 5,222 shares of UroGen Pharma Ltd. (URGN) at $27.30 ($0.14M total) on 2026-06-08.
1 min readThis page on Stock Titan provides a comprehensive resource for Urogen Pharma (URGN) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K material event reports, and insider trading forms. It aggregates regulatory disclosures for the Israel-organized biotechnology issuer listed on The Nasdaq Stock Market. The platform also offers AI-powered summaries, impact scoring, and sentiment analysis for each filing, helping investors quickly understand complex financial and governance information.
5 min readUroGen Pharma Ltd. announced the publication of pivotal Phase 3 ENVISION trial results for ZUSDURI™ (mitomycin) in The Journal of Urology. The study demonstrated a 72.2% probability of remaining event-free at 24 months after achieving a complete response at three months in adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). ZUSDURI, the first FDA-approved therapy for this condition, offers a non-surgical treatment potentially breaking the cycle of repeated recurrences and surgeries.
2 min read
